AMGN News and Press, Amgen Inc. From 05/26/24

2024-05-26 06:53:00 ET With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen 's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-24 11:03:44 ET Summary The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst month for the stock market, with unpredictable ret...

2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for AMGN on May 22, 2024 05:12AM ET. The previous analyst recommendation was Overweight. AMGN was trading at $314.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-22 05:30:00 ET Summary Matrix Asset Advisors is a registered investment advisor. The firm is 100% owned by its employees. Matrix is led by David A. Katz, CFA, a co-founder of Matrix, who created the firm’s investment valuation models. Matrix’s Large Cap Value...

2024-05-21 16:27:16 ET Summary Amgen Inc. stock is challenging the $320 resistance level after a recent uptrend. Technical indicators suggest short-term upward momentum and strong buying pressure. EPS growth outlook and robust pipeline support the Amgen breakout from a fundame...

2024-05-20 21:04:09 ET Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024, 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations Ja...

2024-05-20 12:49:46 ET More on Amgen, AstraZeneca Amgen Could Become A Real Contender In The Obesity Market Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending AstraZeneca to build $1.5B ADC manufacturing plant in Singapore Bioph...

NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD PR Newswire Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels ...

2024-05-19 06:15:00 ET Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same mol...